Definition
21 CFR Part 1271 is the FDA's comprehensive regulatory framework for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), establishing four core requirements — establishment registration and product listing, donor eligibility determination, current good tissue practice (cGTP), and labeling — that apply to all HCT/P manufacturers, and defining the Section 361 criteria that determine whether a product requires only Part 1271 compliance or full premarket approval as a drug or biologic.
Comprehensive Definition
21 CFR Part 1271 is the primary federal regulation governing the manufacture and distribution of human cells, tissues, and cellular and tissue-based products (HCT/Ps) in the United States. Promulgated by the FDA under Section 361 of the Public Health Service Act (42 U.S.C. § 264), Part 1271 was designed to prevent the introduction, transmission, or spread of communicable diseases through HCT/P transplantation, while establishing a risk-based regulatory framework that allows minimally processed tissues to be used for their established clinical applications without the burden of full drug or biologic premarket approval.
Part 1271 applies to any establishment that performs any step in the manufacture of an HCT/P, including recovery, donor screening, donor testing, processing, storage, labeling, packaging, and distribution. The regulation establishes four core requirements. First, registration and listing: establishments must register with the FDA within five days of beginning operations and must list each HCT/P they manufacture. Registration is maintained through the FDA's Unified Registration and Listing System (URLS). Second, donor eligibility: establishments must screen and test donors for relevant communicable disease agents and diseases, and must determine donor eligibility before the HCT/P is distributed. Third, current good tissue practice (cGTP): establishments must follow manufacturing standards designed to prevent contamination, ensure product quality, and maintain traceability from donor to recipient. Fourth, labeling: HCT/Ps must be labeled with required information including the name of the establishment, a description of the product, and the donor eligibility determination.
The most consequential provision of Part 1271 is the Section 361 exemption framework. An HCT/P that meets four criteria is regulated solely under Part 1271 and does not require premarket approval: (1) minimal manipulation — the processing does not alter the relevant biological characteristics of the cells or tissue; (2) homologous use — the HCT/P is used to perform the same basic function in the recipient as in the donor; (3) not combined with a drug or device (with limited exceptions for water, crystalloids, sterilizing, preserving, or storage agents); and (4) no systemic effect and not dependent on the metabolic activity of living cells for its primary function, or the product is for autologous use, allogeneic use in a first- or second-degree relative, or reproductive use.
HCT/Ps that do not meet all four Section 361 criteria are regulated as drugs, biologics, or devices under Section 351 of the Public Health Service Act or the Federal Food, Drug, and Cosmetic Act, and require premarket approval before they can be marketed. The FDA has taken enforcement action against numerous regenerative medicine clinics for marketing Section 351 products without premarket approval, including warning letters, injunctions, product seizures, and criminal prosecutions.
The FDA's interpretation of the minimal manipulation and homologous use criteria has been clarified through a series of guidance documents, most recently the 2017 guidance (updated 2020) on "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use." This guidance provides detailed examples of what does and does not constitute minimal manipulation and homologous use for various HCT/P types, and is essential reading for any operator in the regenerative medicine space.
Why It Matters
21 CFR Part 1271 is the regulatory foundation of the regenerative medicine industry, and understanding it is non-negotiable for any healthcare operator who offers cell or tissue-based therapies. The consequences of non-compliance are severe: the FDA has issued warning letters to hundreds of regenerative medicine clinics, obtained injunctions shutting down clinics that were marketing unapproved products, and referred cases to the Department of Justice for criminal prosecution. Non-compliance is not a theoretical risk — it is an active enforcement priority for the FDA.
The Part 1271 framework is also important because it defines the boundary between products that can be offered without premarket approval and products that cannot. Many regenerative medicine clinics operate under the mistaken belief that all cell and tissue-based products are "natural" and therefore exempt from FDA regulation. This is incorrect. The FDA's position is that HCT/Ps that do not meet the Section 361 criteria are drugs or biologics that require premarket approval, regardless of whether they are derived from natural sources.
For healthcare operators, the practical implication of Part 1271 is that every HCT/P product offered in the practice must be analyzed against the Section 361 criteria before it is administered. This analysis should be documented and should be reviewed by a regulatory attorney or FDA regulatory consultant. Products that do not clearly meet the Section 361 criteria should not be offered without premarket approval or an Investigational New Drug (IND) application.
Historical Background
The FDA's regulation of human tissues began in the early 1990s in response to reports of HIV transmission through transplanted tissues. The FDA issued its first tissue regulations in 1993, focusing on HIV and hepatitis screening for tissue donors. In 1997, the FDA published a proposed framework for the regulation of HCT/Ps that introduced the concept of a tiered, risk-based regulatory approach based on the degree of manipulation and the intended use of the product.
The final Part 1271 regulations were published in three phases between 2001 and 2005. The registration and listing requirements took effect in 2001, the donor eligibility requirements in 2004, and the cGTP requirements in 2005. The phased implementation was designed to give the industry time to come into compliance with the new requirements.
The regenerative medicine boom of the 2000s and 2010s created significant regulatory challenges as clinics began offering novel cell and tissue-based therapies that pushed the boundaries of the Part 1271 framework. The FDA responded with enforcement actions and guidance documents, culminating in the 2017 guidance documents that significantly clarified the Section 361 criteria and signaled the FDA's intent to enforce the framework more rigorously.
Federal Regulations
21 CFR Part 1271: Human Cells, Tissues, and Cellular and Tissue-Based Products. The primary regulation governing HCT/Ps, including registration and listing (Subpart B), donor eligibility (Subpart C), current good tissue practice (Subpart D), and inspection and enforcement (Subpart E).
Section 361 of the Public Health Service Act: 42 U.S.C. § 264. Authorizes the FDA to make and enforce regulations to prevent the introduction, transmission, or spread of communicable diseases. Section 361 HCT/Ps are regulated solely under Part 1271.
Section 351 of the Public Health Service Act: 42 U.S.C. § 262. Governs the licensure of biological products. HCT/Ps that do not meet the Section 361 criteria are regulated as biological products under Section 351 and require a Biologics License Application (BLA) before marketing.
Federal Food, Drug, and Cosmetic Act: 21 U.S.C. § 301 et seq. HCT/Ps that are more than minimally manipulated or used non-homologously may also be regulated as drugs or devices under the FD&C Act, requiring a New Drug Application (NDA) or Premarket Approval (PMA).
FDA Guidance: Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (2017, updated 2020).
State Considerations
In addition to federal FDA regulation under Part 1271, HCT/P establishments may be subject to state health department licensing requirements, state medical board oversight, and state pharmacy board regulation. Some states have enacted specific regulations for stem cell clinics or regenerative medicine practices.
Florida requires stem cell clinics to provide specific informed consent disclosures to patients, including disclosure that the treatment is experimental and not FDA-approved. California has enacted the Stem Cell Clinic Disclosure Act (Health and Safety Code § 1644 et seq.), which requires stem cell clinics to provide written disclosures to patients before administering any stem cell therapy. Texas has enacted regulations governing the use of stem cell therapies in clinical practice under the Texas Medical Board's rules.
State medical boards have taken disciplinary action against physicians who administer unapproved HCT/P products, and state attorneys general have pursued consumer protection actions against clinics that make unsubstantiated claims about the efficacy of stem cell therapies. Operators must comply with both federal FDA requirements and applicable state requirements.
Common Mistakes
- Not registering with the FDA as an HCT/P establishment before beginning operations — registration is required within five days of beginning to manufacture HCT/Ps, and failure to register is a violation of Part 1271.
- Relying on vendor representations about a product's Section 361 status without conducting independent regulatory due diligence — vendors frequently make inaccurate claims about their products' regulatory status.
- Administering HCT/P products via intravenous infusion for systemic conditions — IV administration for systemic use is a strong indicator that the product is not being used homologously, which would take it outside the Section 361 framework.
- Not maintaining required donor eligibility records and cGTP documentation — failure to maintain required records is a common finding in FDA inspections and can result in warning letters and enforcement actions.
- Offering exosome products as if they are Section 361 HCT/Ps — the FDA has stated that exosomes are not HCT/Ps and are regulated as drugs or biologics requiring premarket approval.
- Not staying current with FDA guidance documents and enforcement actions in the regenerative medicine space — the FDA's interpretation of the Part 1271 framework has evolved significantly and continues to evolve.
Operator Insight
21 CFR Part 1271 is the most important regulatory document in regenerative medicine, and it is also the most frequently misunderstood. I work with operators who have been offering cell and tissue-based therapies for years without ever reading Part 1271 or understanding the Section 361 criteria. They are operating on the assumption that their vendor has done the regulatory work for them — and that assumption is often wrong. The first thing I tell every regenerative medicine operator is to read the FDA's 2020 guidance on minimal manipulation and homologous use. It is not a long document, and it provides clear examples of what does and does not meet the Section 361 criteria for the most common HCT/P types. If you cannot clearly articulate why each product you offer meets the Section 361 criteria, you need to stop offering it until you can. The second thing I tell operators is to register with the FDA as an HCT/P establishment if you are manufacturing HCT/Ps. Many operators do not realize that processing autologous cells — even in the same procedure — may trigger registration requirements. Consult with a regulatory attorney to determine whether your specific activities require registration, and if they do, register before you begin operations.
— AJ Pakpour, Healthcare Practice Startup & Strategy Expert
In Practice
A regenerative medicine clinic offering amniotic membrane injections, PRP, and BMAC conducts a regulatory audit with a healthcare attorney. The attorney reviews each product against the Section 361 criteria. The amniotic membrane product is confirmed to meet the Section 361 criteria for intra-articular and soft tissue injection use. PRP is confirmed to be exempt from HCT/P regulation for same-procedure autologous use. BMAC is confirmed to meet the Section 361 criteria for orthopedic use. The clinic registers with the FDA as an HCT/P establishment, implements donor eligibility and cGTP procedures for the amniotic membrane product, and documents the regulatory analysis for each product in its compliance files. An FDA inspector visits a regenerative medicine clinic that has been administering umbilical cord blood products via intravenous infusion for conditions including multiple sclerosis, autism, and Parkinson's disease. The inspector determines that the IV administration of umbilical cord blood for these conditions does not constitute homologous use — umbilical cord blood does not perform the same basic function in the recipient as it did in the donor when used to treat neurological conditions. The FDA issues a warning letter requiring the clinic to cease marketing the product and to submit a Biologics License Application if it wishes to continue offering the therapy.
Frequently Asked Questions
References
Further Reading
Turn Knowledge Into Action
Apply what you just learned. Book a strategy session with AJ Pakpour — healthcare practice startup and strategy expert.
Book a Strategy Session